MDNA Life Sciences has entered into an exclusive license agreement with LabCorp® (LH) to develop and commercialize a non-invasive test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA “grey zone”.
MDNA Life Sciences announces that it has entered into an exclusive license agreement with its first international commercial partner.
MDNA Life Sciences has entered into a collaboration agreement with the University of Oxford to further the development and validation of MDNA’s non-invasive blood-based test for endometriosis.
A clinical study published in the American Health & Drug Benefits journal describes the Mitomic Prostate Core Test’s impact on patient management and the biopsy decision-making process.